A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction

PharmacoEconomics

Volumn 24, Issue 8, 2006, Pages 783-795

  Lamotte, Mark ^a   Annemans, Lieven ^a,b   Kawalec, Pawel ^c,d   Zoellner, York ^e  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c Health Technology Assessment Center   (Poland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; TOCOPHEROL;

ADULT; ANAMNESIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; ECONOMIC EVALUATION; ENVIRONMENTAL FACTOR; GEOGRAPHY; HEALTH CARE COST; HEALTH ECONOMICS; HEART DISEASE; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL SOCIETY; MONTE CARLO METHOD; MORTALITY; PRIORITY JOURNAL; REVASCULARIZATION; SENSITIVITY ANALYSIS; STROKE; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; FATTY ACIDS, OMEGA-3; HUMANS; LIFE EXPECTANCY; MIDDLE AGED; MONTE CARLO METHOD; MYOCARDIAL INFARCTION;

EID: 33747203207     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624080-00005     Document Type: Article

References (35)

1. Braunwald E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 1998; 352: 1771-4
2. Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000; 21: 1833-40
3. Haffner SM, Lehto S, R̈onnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
4. Lampe FC, Whincup PH, Wannamethee SG, et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur Heart J 2000; 21: 1052-62
5. de Lorgeril M, Salen P. Diet as preventive medicine in cardiology. Curr Opin Cardiol 2000; 15: 364-70
6. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001; 345: 1473-81
7. Myerburg RJ, Spooner PM. Opportunities for sudden death prevention: directions for new clinical and basic research. Cardiovasc Res 2001; 50: 177-85
8. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-450
9. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55
10. Marchioli R, on behalf of the GISSI-Prevenzione Investigators. Treatment with n-3 polyunsaterated fatty acids after myocardial infarction: results of the GISSI-Prevenzione Trial. Eur Heart J Suppl 2001; 3 Suppl. D: D85-97
11. Franzosi MG, Brunetti M, Marchioli R, et al. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001; 19: 411-20
12. International Society of Pharmacoeconomics and Outcomes Research [online]. Available from URL: http://www.ispor.org/PEguidelines/ [Accessed 2005 Sep]
13. Organisation for Economic Co-operation and Development website [online]. Available from URL: http://www.oecd.p4.siteinternet.com/publications/doifiles/ 302006011P1-10-01-04-t01.xls [Accessed 2006 Jan]
14. Economic Policy Committee 2001. Budgetary challenges posed by ageing populations: the impact on public spending on pensions, health and long-term care for the elderly and possible indicators of the long-term sustainability of public finances [online]. Available from URL: http://www.efrp.org/downloads/ eu_publications/Budgetary_challenges.pdf [Accessed 2006 January]
15. Australian Government Department of Health and Ageing. Public sector estimated cost weights round 8 AR-DRG v5.0 [online]. Available from URL: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ BB918453BBAB7AB0CA2570C1000230B0?.OpenDocument [Accessed 2006 Jan]
16. Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24: 45-50
17. DRG Research group, Universitätsklinikum [online]. Available from URL: http://drg.uni-muenster.de/ kodierung/kodierung.html [Accessed 2005 Sept]
18. Haldemann R, Luscher TF, Szucs TD. Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study. Schweiz Rundsch Med Prax 2001 Mar 29; 90: 539-45
19. Lamotte M, Caekelbergh K, Annemans L, et al. Assessment of the cost of cardiovascular death [abstract]. Value Health 2003; 6: 658
20. Jones PJ, Lau VW. Effect of n-3 polyunsaturated fatty acids on risk reduction of sudden death. Nutr Rev 2002 Dec; 60 (12): 407-9
21. Statistics Canada. Canadian specific medical inflation index [online]. Available from URL: http://www40.statcan.ca/101/cst01/econ150a.htm [Accessed 2006 Jan]
22. National Sickness Fund. Catalogue of Polish National Sickness Fund [Excel]. 2004
23. Annemans L, Lamotte M, Levy E, et al. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Med Econ 2003; 6: 55-68
24. Coy P, Schaafsma J, Schofield JA. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000 Nov 1; 48 (4): 1025-33
25. Mauskopf JA, Cates SC, Griffin AD, et al. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000; 17: 611-20
26. Abhyankar B. Further reduction in mortality following myocardial infarction. Hosp Med 2002; 63: 610-4
27. Euroaspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from Euroaspire II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72
28. Christensen JH, Riahi S, Schmidt EB, et al. n-3 Fatty acids and ventricular arrhythmias in patients with ischaemic heart disease and implantable cardioverter defibrillators. Europace 2005; 7: 338-44
29. Brouwer IA, Zock PL, Wever EF, et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n-3 fatty acids and incidence of cardiac arrhythmia: SOFA. Eur J Clin Nutr 2003; 57: 1323-30
30. Mozaffarian D, Ascherio A, Hu FB, et al. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005; 111: 157-64
31. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82
32. Pharoah PDP, Hollingworth W. Cost-effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443-8
33. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001; 141: 727-34
34. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 Suppl.: S111-6
35. Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial. The platelet IIa/IIb in unstable angina: receptor suppression using integrilin therapy. Eur Heart J 2002 Jan; 23 (1): 50-8